ESMO Congress 2026

Immune checkpoint blockade is a drug class with accumulated evidence in genitourinary oncology, yet its benefit varies markedly by tumor type and setting: in a real-world retrospective study across five European institutions covering 287 patients with synchronous metastatic renal cell carcinoma (s-mRCC), nivolumab plus ipilimumab yielded a median overall survival (OS) of 29.0 months (95% CI 20.1–36.2) for the overall cohort, 49.8 months (95% CI 33.1–not reached) for the intermediate-risk group and 16.3 months (95% CI 13.5–26.3) for the poor-risk group (HR 0.50, 95% CI 0.35–0.71) ^[2]. By contrast, for the mechanistic class RIPTAC belongs to—using AR as a guide to deliver the hit to BRD4 and disrupt transcription—no same-class clinical data are available within these materials, so the evidence base must start from early trials.

At ESMO2026, the Uromigos podcast followed two readouts in two episodes. In Episode 524, Dr. Ben Garmezy joins Brian and Tom to discuss Phase 1 data on RIPTAC in prostate cancer: this novel mechanism uses the androgen receptor (AR) to target BRD4 and disrupt cancer cell transcription, with no efficacy or safety figures disclosed in the post. In Episode 521, Dr. Rob Jones unpacks two Phase 3 trials presented at the meeting—in muscle-invasive bladder cancer (MIBC), neither demonstrated a benefit from adding immunotherapy to chemotherapy—and the discussion covers how these findings fit alongside the NIAGARA data and the implications for neoadjuvant and adjuvant strategies; the specific endpoints and effect sizes of the two trials are likewise not given in the post.

There are two layers of progress. The two negative Phase 3 readouts in MIBC stand in contrast to the long-term survival benefit of checkpoint blockade in metastatic renal cell carcinoma ^[2], showing that the value of the same class must be verified separately by tumor type and treatment stage, and making post-NIAGARA decisions on perioperative immunotherapy far less one-size-fits-all. RIPTAC, meanwhile, opens a different route at the mechanism level: rather than inhibiting AR directly, it treats AR as a homing device, guiding the transcriptional hit against BRD4 into cancer cells; if the Phase 1 signal holds, prostate cancer would gain an additional therapeutic concept, though for now everything rests on the mechanistic description and Phase 1 positioning.

The limitations are equally clear: RIPTAC is Phase 1 only with key numbers undisclosed, the two MIBC Phase 3 trials lack verifiable figures in the post, and the renal cell carcinoma evidence in the background comes from a retrospective real-world cohort ^[2], which can only serve as a reference for contextualizing immunotherapy benefit and cannot be directly extrapolated to the perioperative bladder cancer setting.